GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nkarta Inc (NAS:NKTX) » Definitions » Return-on-Tangible-Equity

Nkarta (Nkarta) Return-on-Tangible-Equity : -31.62% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Nkarta Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Nkarta's annualized net income for the quarter that ended in Mar. 2024 was $-118.07 Mil. Nkarta's average shareholder tangible equity for the quarter that ended in Mar. 2024 was $373.47 Mil. Therefore, Nkarta's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was -31.62%.

The historical rank and industry rank for Nkarta's Return-on-Tangible-Equity or its related term are showing as below:

NKTX' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -61.79   Med: -36.47   Max: -30.09
Current: -34.01

During the past 6 years, Nkarta's highest Return-on-Tangible-Equity was -30.09%. The lowest was -61.79%. And the median was -36.47%.

NKTX's Return-on-Tangible-Equity is ranked better than
57.24% of 1305 companies
in the Biotechnology industry
Industry Median: -46.56 vs NKTX: -34.01

Nkarta Return-on-Tangible-Equity Historical Data

The historical data trend for Nkarta's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nkarta Return-on-Tangible-Equity Chart

Nkarta Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial - -61.79 -30.09 -36.53 -36.41

Nkarta Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34.29 -40.07 -33.37 -38.95 -31.62

Competitive Comparison of Nkarta's Return-on-Tangible-Equity

For the Biotechnology subindustry, Nkarta's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nkarta's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nkarta's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Nkarta's Return-on-Tangible-Equity falls into.



Nkarta Return-on-Tangible-Equity Calculation

Nkarta's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-117.501/( (372.207+273.285 )/ 2 )
=-117.501/322.746
=-36.41 %

Nkarta's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-118.072/( (273.285+473.651)/ 2 )
=-118.072/373.468
=-31.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Nkarta  (NAS:NKTX) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Nkarta Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Nkarta's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Nkarta (Nkarta) Business Description

Industry
Traded in Other Exchanges
N/A
Address
6000 Shoreline Court, Suite 102, South San Francisco, CA, USA, 94080
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.
Executives
Paul J Hastings director, officer: See Remarks 61 HARTFORD STREET, SAN FRANCISCO CA 94114
David Shook officer: Chief Medical Officer 6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Alicia J. Hager officer: Chief Legal Officer C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Ralph Brandenberger officer: Sr. VP, Technical Operations 6000 SHORELINE COURT, SUITE 102, SAN FRANCISCO CA 94080
James Trager officer: Chief Scientific Officer 6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Alyssa Levin officer: See Remarks 6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Nadir Mahmood officer: Chief Business Officer 6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Simeon George director 161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Angela Thedinga director C/O ADVERUM BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, MENLO PARK CA 94025
Ra Capital Nexus Fund, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kanya Rajangam officer: Chief Medical Officer C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Plc Glaxosmithkline director, 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900